PLRX Pliant Therapeutics Inc

Price (delayed)

$13.26

Market cap

$799.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$738.8M

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual ...

Highlights
The revenue has dropped by 97% year-on-year and by 84% since the previous quarter
PLRX's gross profit has dropped by 97% year-on-year and by 84% since the previous quarter

Key stats

What are the main financial stats of PLRX
Market
Shares outstanding
60.33M
Market cap
$799.92M
Enterprise value
$738.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.83
Price to sales (P/S)
3,217.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,979.02
Earnings
Revenue
$248,000
EBIT
-$169.34M
EBITDA
-$164.98M
Free cash flow
-$118.61M
Per share
EPS
-$2.87
Free cash flow per share
-$1.97
Book value per share
$7.26
Revenue per share
$0
TBVPS
$8.67
Balance sheet
Total assets
$521.61M
Total liabilities
$84.27M
Debt
$54.66M
Equity
$437.33M
Working capital
$459.51M
Liquidity
Debt to equity
0.12
Current ratio
16.12
Quick ratio
15.92
Net debt/EBITDA
0.37
Margins
EBITDA margin
-66,523%
Gross margin
100%
Net margin
-68,848%
Operating margin
-78,404%
Efficiency
Return on assets
-31.8%
Return on equity
-35.1%
Return on invested capital
-37%
Return on capital employed
-34.5%
Return on sales
-68,282.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLRX stock price

How has the Pliant Therapeutics stock price performed over time
Intraday
4.49%
1 week
6.51%
1 month
21.43%
1 year
-24.87%
YTD
-26.78%
QTD
23.35%

Financial performance

How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$248,000
Gross profit
$248,000
Operating income
-$194.44M
Net income
-$170.74M
Gross margin
100%
Net margin
-68,848%
The revenue has dropped by 97% year-on-year and by 84% since the previous quarter
PLRX's gross profit has dropped by 97% year-on-year and by 84% since the previous quarter
PLRX's operating income is down by 38% year-on-year and by 6% since the previous quarter
The net income has contracted by 29% YoY and by 6% from the previous quarter

Growth

What is Pliant Therapeutics's growth rate over time

Valuation

What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
1.83
P/S
3,217.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,979.02
The EPS has declined by 4.4% since the previous quarter
PLRX's price to book (P/B) is 38% lower than its 5-year quarterly average of 2.8 and 17% lower than its last 4 quarters average of 2.1
The equity has contracted by 22% YoY and by 8% from the previous quarter
The P/S is 157% more than the last 4 quarters average of 1198.5
The revenue has dropped by 97% year-on-year and by 84% since the previous quarter

Efficiency

How efficient is Pliant Therapeutics business performance
The ROE has declined by 13% since the previous quarter but it is up by 10% year-on-year
The company's return on invested capital rose by 11% YoY but it fell by 9% QoQ
Pliant Therapeutics's return on assets has increased by 10% YoY but it has decreased by 10% QoQ

Dividends

What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLRX.

Financial health

How did Pliant Therapeutics financials performed over time
The total liabilities has soared by 134% YoY and by 118% from the previous quarter
The company's quick ratio fell by 37% YoY and by 8% QoQ
Pliant Therapeutics's debt is 88% lower than its equity
The equity has contracted by 22% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.